Keros Therapeutics (KROS) Depreciation & Amortization (CF) (2019 - 2025)
Keros Therapeutics filings provide 7 years of Depreciation & Amortization (CF) readings, the most recent being $400000.0 for Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) rose 20.48% to $400000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 22.78% increase, with the full-year FY2025 number at $1.5 million, up 22.78% from a year prior.
- Depreciation & Amortization (CF) hit $400000.0 in Q4 2025 for Keros Therapeutics, up from $395000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $400000.0 in Q4 2025 to a low of $80000.0 in Q1 2021.
- Median Depreciation & Amortization (CF) over the past 5 years was $228500.0 (2023), compared with a mean of $230250.0.
- Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 238.46% in 2022 and later crashed 37.99% in 2023.
- Keros Therapeutics' Depreciation & Amortization (CF) stood at $104000.0 in 2021, then grew by 22.12% to $127000.0 in 2022, then surged by 94.49% to $247000.0 in 2023, then skyrocketed by 34.41% to $332000.0 in 2024, then rose by 20.48% to $400000.0 in 2025.
- The last three reported values for Depreciation & Amortization (CF) were $400000.0 (Q4 2025), $395000.0 (Q3 2025), and $370000.0 (Q2 2025) per Business Quant data.